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Introduction
Medication adherence, which can be defined as taking medication as prescribed or as "the extent to which a person's behavior coincides with medical or health advice" (1) , is an essential component of a successful health outcome (2, 3) . Both clinical experience and the literature describe medication adherence as frequently inadequate: at least 50% of patients unintentionally omit doses (3) (4) (5) (6) (7) . Adherence is particularly important in chronic diseases: the average adherence with long-term medical regimens is estimated at 50% to 65% (8) .
Measurement of medication adherence has been recognized as an important factor in medical care and treatment outcome (1, 9) . Moreover, the CONSORT statement for the reporting of randomized controlled trials recommends showing the flow of participants through each stage of a randomized controlled trial and including, in the item for follow-up, "the number of participants who completed treatment as allocated and the number who did not complete treatment as allocated, by study group" (10) .
Completing treatment includes the notion of taking the medication (i.e., adherence).
Furthermore, the International Conference on Harmonisation (ICH) guidelines also include recommendations to report adherence: "the measures taken to ensure and document treatment adherence should be described, e.g., drug accountability, diary cards, blood, urine or other body fluid drug level measurements, or medication event monitoring" (11) . Thus adherence is an important issue in clinical practice in chronic diseases and has been recognized by major instances as an important issue for randomized controlled trials.
However, data on whether these recommendations are applied or the methodological issues of medication adherence for randomized controlled trials are lacking (12, 13) and even articles describing adherence consider it only in a particular context (e.g., definitions of adherence when electronic event-monitoring devices are used) (13) .
The complexity of the problem regarding adherence has prevented the development of a gold standard method of measurement and the lack of a valid measure of nonadherence is itself a major barrier to adherence research. The first methodological difficulty in the issue of medication adherence is assessment.
Several methods to assess adherence have been proposed; some are based on patient recall (patient diary, patient questionnaire 9 ), and others on more objective methods (pill count, blood drug concentrations, or devices such as electronic medication-event monitoring 3, 14 ) . To our knowledge, no systematic review of the techniques used to measure adherence in clinical trials exists. Another difficulty concerns the reporting of adherence. Adherence can be reported either as a quantitative measure (i.e., as a proportion of prescribed treatment) or as a qualitative measure, i.e., adherent versus nonadherent patients). Finally, another aspect of interest concerns the possible effect of nonadherence on the interpretation of trial results. For example, for a given sample size, nonadherence, like follow-up loss, lowers the study power (15) .
The objectives of this study were to 1) evaluate recent publications of randomized controlled trials of treatment of 6 chronic diseases (HIV infection, asthma, rheumatoid arthritis, diabetes mellitus, hypertension, and osteoporosis) to determine documentation of frequency of medication adherence assessment and 2) determine which methods are used to assess and report adherence. The goal is not to be exhaustive but, rather, to report a "pilot study" of methodological issues concerning adherence.
Material and methods
A systematic review of recent randomized controlled trials was performed.
Publications of 6 major chronic diseases were included: HIV infection, asthma, rheumatoid arthritis, diabetes mellitus, hypertension, and osteoporosis. These diseases offer a range of different situations and potentially different methodological difficulties for assessing adherence, since some are asymptomatic and some require polymedication.
Search strategy
We selected publications of all randomized controlled clinical trials assessing self- Publications were identified in the Medline database through a search that used the following exploded MeSH terms: "asthma OR antiasthmatic agents," "diabetes mellitus," "rheumatoid arthritis," "HIV infections OR acquired immunodeficiency syndrome," "hypertension OR antihypertensive agents," and "osteoporosis," with a limitation to "Randomized Clinical Trials", "Humans" and English-language articles.
Publications were included only if the study design was identified as a randomized controlled clinical trial, published as a full-text article and assessed a pharmacological treatment self-administered by adult patients with one of the 6 selected diseases. Results of the article selection process are reported in Figure 1 (date of article selection process: February 17, 2005).
Method for evaluation of publications
Publications were evaluated based on the full-text articles. The reviewer was not blinded to the journal name and the authors, as evidence concerning the effect of masking on assessments of trial quality is inconsistent (16, 17) .
A standardised checklist of items was used to collect data from each article. Abstracted data included year of publication, funding sources (public or private either clearly reported or extrapolated from authors' affiliations), number of centers involved, underlying disease, trial duration, type of treatment assessed (symptom modifying versus disease controlling), number of treatments taken simultaneously by a patient during the trial and planned in the study design (even if only some of these treatments were evaluated), route of administration (oral, topical, subcutaneous, inhalation, other).
The quality of the publications was determined by use of the Jadad scale (18) (score 0 to 5) and the Delphi list (19, 20) (score 0 to 9). A high score indicates high quality for both scales.
Evaluation of adherence

Assessment and reporting of adherence
It was checked whether adherence was described as being assessed in the 
Reporting of trial results
It was checked whether adherence was an outcome measure for the trial, and since nonadherence can lower the power of a study (15) , it was checked whether nonadherence was taken into account in the sample size calculations.
Elements associated with reporting of adherence in a publication
As an exploratory analysis, it was checked what elements predicted reporting of adherence. The trial or publication characteristics investigated for association with reporting of adherence (yes/no) were the disease, journal, journal impact factor, type of funding, number of patients, trial duration, number of centers, dates of the trial, whether it was the first publication from a trial, intention-to-treat analysis and methodologic quality of the publication. reporting of adherence (yes/no) and trial and publication characteristics. All data analyses involved use of the Statistical Analysis System (SAS) version 9.1.
Statistical analysis
Results
Selected publications
Of the 637 publications identified, 192 were included in the analysis (Figure 1 ). The 445 publications excluded were mainly not randomized controlled trials (n=91), not assessing a pharmacological therapeutic intervention (n=131), or not about the selected diseases (n=72).
The characteristics of the publications are given in Table 1 Items of the CONSORT diagram (11) (flow of participants through each stage of the trial) were reported in a flow chart or in the text in 68.3% of the publications.
The median quality of the articles was high: 3 on the 5-point Jadad scale and 7 on the 9-point Delphi list. 
Assessment of adherence
Adherence was described as assessed in 69 (35.9%) publications. However, data on methods of assessment was missing in 8 of these (11.6%). Table 2 shows the techniques described to assess adherence according to the disease. The techniques most frequently described were pill count (n= 34, 49.3% of the 69 publications) and patient diary (n= 15, 21.7%), but patient diary was the only technique in only 8 of the publications (11.6%).
Two or more techniques were described in 18 publications (26.1%) and this was not more frequent in one disease than in another (p=0.85). Separate results for the different techniques were given in only 2 of these publications (11.1%); in fact, in all the other cases determining which of the techniques had produced the given results was impossible. In most cases (n= 60 publications, 86.7% of 69), all patients were evaluated for adherence. Assessments of adherence were described as performed at every visit in 44 (63.8%) cases, at specified visits in 11 (15.9%), and this was not available in 14 (20.3%). When several drugs were taken, it was not always clear which drugs were evaluated for adherence (data unclear in 12 publications, 37.5% of 32 publications with several drugs and assessment).
Reporting of adherence
Adherence was reported in 64 publications (33.3%). However in 21 articles (10.9%)
adherence was reported to be assessed but no results were given, and in 26 other articles (13.5%) no elements for how adherence was assessed were given, but adherence results were reported (this explains discrepancies between assessment and reporting of adherence as seen Reports defining adherence qualitatively (n= 41; 21.4%) described a cutoff point (e.g., a patient was nonadherent if intake was less than 80% of total medication). In 10 reports (24.4%) several cutoffs were described. In 8 publications, cutoff was 80% of medication, and in 6 cutoff was 80% of treatment for 80% of the time. In 7 publications, a definition of adherence was "patients totally adherent," and other cutoffs used (19 times) varied among studies, ranging from "at least one intake (>0%)" to "patients missing just one dose." In 3 cases (7.3%), the cutoff used was unclear. In 23 publications (12.0%), "number of patients excluded for nonadherence" was reported, mainly presented in the CONSORT flow chart (18 publications).
When adherence was reported as a quantitative measure, we could distinguish between dose-taking and dose-timing adherence. Dose-taking measures (quantitative adherence) assess whether the appropriate number of doses were taken and dose-timing measures assess whether the doses were taken within the appropriate time interval during the day (e.g., within 25% of the dosing interval).
Dose-timing adherence was described in only 4 publications (the same 4 publications describing electronic monitoring assessment). In only these reports were extra doses (not just missed doses) also taken into account for the definition of adherence.
Adherence results and trial results
When adherence was reported as a qualitative measure (41 publications), the median percentage of "nonadherent" patients was 6.2% (range 0-63.3%) and was similar across the treatment arms, when reported. In the 27 publications in which adherence was reported as a quantitative measure, the median reported adherence was 93% (i.e., intake of 93% of the medication prescribed over the trial duration, range 63.5-100%). Adherence was reported separately in the different trial arms in 41 publications (64.1%), and 22 (31.9%) specified whether adherence was similar in the treatment arms.
Adherence was described as an outcome measure in 5 cases (2.6%). Five publications (2.6%) documented a run-in period where adherence was evaluated.
Calculation of the sample size was reported in 125 (65.1%); however, the sample size took into account predicted nonadherence in only 2 (1.6% of 125).
The probability value for the primary outcome measure was available in 164 reports (82.8%); in 130 (79.3%) the p value was significant (<0.05) and did not differ according to whether adherence was reported or not (p=0.68).
Elements associated with reporting of adherence
The exploratory multivariate analysis revealed that the only elements associated with reporting of adherence were the methodologic quality of the publication (Jadad
Discussion
This study assessed the methodological variability in the field of medication adherence in reports of randomized controlled trials of self-administered pharmacological interventions for 6 chronic diseases published over 2 years in highimpact general medical and specialty journals. To our knowledge, this is the first description of methods used to assess adherence in a diverse sample of trials in different chronic conditions. It provides an unprecedented look into the assessment and reporting of adherence in randomized controlled trials, revealing some clear and relevant disparities in the definitions of adherence and methods used to report the results.
The CONSORT statement and the ICH guidelines both encourage the reporting of adherence (10, 11) . Despite consistent recommendations for reporting adherence in clinical trials, our literature review showed results for adherence were reported in only 33% of the publications we assessed, and even less often were assessment methods and results given (25%). Furthermore, in the 33% publications, adherence was reported as extremely high. Of course, these results give rise to speculation regarding the results in the other studies that did not report adherence. Thus, a
discrepancy exists between what is recommended and what we observed, even in recent reports published in high-impact-factor journals with a high methodological quality (both according to the Jadad scale and the Delphi list).
There are some possible explanations for this discrepancy. A simple explanation could arise from size constraints for published articles, which force the authors, sometimes even at the reviewers' instigation, to omit some elements from their publications (21) . In favour of this explanation, we note that 22 publications (11.5%) included some information on either assessment or definition of adherence but no results on adherence. Thus, a limitation to our study is that we assessed only publications of randomized controlled trials, not the trials themselves.
Another important element that could explain the underreporting of adherence is related to the methodological difficulties of how to assess and synthesize and report the results of adherence. As indicated by our literature review, to date no consensus exists on these aspects. In the evaluated publications, adherence was assessed mainly by pill count, but many other techniques were used. Methods of assessment were detailed in only 31.8% of publications, despite literature indicating that results of adherence depend greatly on the technique of assessment (22) (23) (24) (25) (26) .
We also noted great heterogeneity in the definitions of adherence, whether proportion of the medication prescribed or adherent patient (yes/no), and in the latter case, a large range of cutoffs was described. When adherence was defined as a quantitative measure, it was almost always a proportion of the prescribed treatment taken. For qualitative cutoffs, the most frequent cutoff was "patient excluded for nonadherence," which is not a reproducible definition of nonadherence and indeed can refer to nonadherence to the protocol as well as to the treatment. When a numerical cutoff was given for nonadherence, results varied widely among diseases studied and for a given disease, which makes comparisons between studies (and interpretations of differences in effect size) difficult.
Results of clinical trials can be influenced by patient adherence (27, 28) .
Nonadherence leads to loss of power for a given sample size, which can lead to negative results for trials (15) , even if a treatment is efficacious, and this element was rarely taken into account in the publications we assessed. Treatment failures that are usually assumed to be medication failures may be a result of nonadherence rather than lack of efficacy. Thus, adherence should be reported and considered when interpreting the results of a trial.
The limitations of our study include the selection of high-impact-factor journals. We chose these journals because a high impact factor is a good predictor of higher methodological quality of journal articles (29) and because our goal was not to be exhaustive but, rather, to raise awareness of methodological issues concerning assessment and reporting of adherence. Furthermore, since we found reporting of adherence to be associated with methodological quality, we doubt that adherence could be reported more in low-impact-factor journals. Another limitation is that we chose only 6 diseases; however, these diseases represent a range of difficulties with regard to adherence. This comparison allowed us to point out that adherence was significantly more often mentioned in reports of osteoporosis, asthma and HIV infection, which may reflect the habits and methods of disease trialists.
To our knowledge, this is the first study comparing the methodology used to measure adherence in different diseases. Clearly, there is room for standardization across specialties. Finally, we have studied only chronic diseases; but chronic diseases are the most relevant for studying adherence, since chronic conditions carry with them the issue of medication adherence (8) .
In conclusion, this study allowed us to point out the real difficulties in the assessment, definition and reporting of medication adherence in randomized controlled trials. Reporting adherence is widely recommended (10, 11) ; furthermore, to allow comparisons of trials by systematic review and meta-analysis, our study highlights the need for further research in this domain for standardization of the assessment, definition and reporting of medication adherence in trials. In particular, emphasis should to be given to determining which measure of adherence is preferable. 
